Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab ± IBI305 plus pemetrexed/cisplatin vs placebo plus pemetrexed/cisplatin in EGFR-mutant non-squamous NSCLC after EGFR-TKI failure
CTR20190972Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab, bevacizumab in Non-small cell lung cancer (NS-NSCLC), Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Innovent Biologics. Started Jun 2019; status: completed.
02
Drugs
sintilimabbevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on CTR20190972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190972.